Literature DB >> 26510857

Right-Sizing Adjuvant and Neoadjuvant Clinical Trials in Breast Cancer.

Donald A Berry1.   

Abstract

I describe a simple and intuitive method for finding sample size for clinical trials in primary breast cancer based on neoadjuvant trial results and using the FDA's patient-level meta-analysis. Then I explain a problem with this method and how the problem can be remedied. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Year:  2015        PMID： 26510857      PMCID： PMC4703523          DOI： 10.1158/1078-0432.CCR-15-1903

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Neoadjuvant Therapy in Breast Cancer as a Basis for Drug Approval.

Authors:  Donald A Berry; Clifford A Hudis
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

2.  Planning the size and duration of a clinical trial studying the time to some critical event.

Authors:  S L George; M M Desu
Journal:  J Chronic Dis       Date:  1974-02

Review 3.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

Authors:  Patricia Cortazar; Lijun Zhang; Michael Untch; Keyur Mehta; Joseph P Costantino; Norman Wolmark; Hervé Bonnefoi; David Cameron; Luca Gianni; Pinuccia Valagussa; Sandra M Swain; Tatiana Prowell; Sibylle Loibl; D Lawrence Wickerham; Jan Bogaerts; Jose Baselga; Charles Perou; Gideon Blumenthal; Jens Blohmer; Eleftherios P Mamounas; Jonas Bergh; Vladimir Semiglazov; Robert Justice; Holger Eidtmann; Soonmyung Paik; Martine Piccart; Rajeshwari Sridhara; Peter A Fasching; Leen Slaets; Shenghui Tang; Bernd Gerber; Charles E Geyer; Richard Pazdur; Nina Ditsch; Priya Rastogi; Wolfgang Eiermann; Gunter von Minckwitz
Journal:  Lancet       Date:  2014-02-14       Impact factor: 79.321

4.  Relationship between Complete Pathologic Response to Neoadjuvant Chemotherapy and Survival in Triple-Negative Breast Cancer.

Authors:  Christos Hatzis; W Fraser Symmans; Ya Zhang; Rebekah E Gould; Stacy L Moulder; Kelly K Hunt; Maysa Abu-Khalaf; Erin W Hofstatter; Donald Lannin; Anees B Chagpar; Lajos Pusztai
Journal:  Clin Cancer Res       Date:  2015-08-18       Impact factor: 12.531

5.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544
  5 in total
  1 in total

1.  Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis.

Authors:  Donald A Berry; Shouhao Zhou; Howard Higley; Lata Mukundan; Shuangshuang Fu; Gregory H Reaman; Brent L Wood; Gary J Kelloff; J Milburn Jessup; Jerald P Radich
Journal:  JAMA Oncol       Date:  2017-07-13       Impact factor: 31.777
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.